drugset / Trial / NCT00316420
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
Timeline
- Start
- 2003-12
- Primary completion
- 2009-02
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 650 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 750 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 950 mg/m2 | Oral |
| Subject | Gemcitabine | Small molecule | 750 mg/m2 | Intravenous |